Reference Population for Speckle Tracking Imaging

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

91 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-12-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The SCAR study uses a software program entitled QLAB, a proprietory program, developed by Philips Healthcare (Philips Healthcare, Andover, MA). Literature on two-dimensional speckle tracking imaging (2DSTE) is growing, but data relevant to the population in the SCAR study is minimal. Accumulation of data relevant for a population of subjects will provide a set of normal values for interpretation of 2DSTE and minimize any influences from differences in data produced from different companies. This data may also assist other researchers investigate other cardiac diseases and abnormalities.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis

NCT01230918

Hypertrophic Cardiomyopathy Acute Coronary Syndrome

TERMINATED PHASE2

Magnetic Resonance Spectroscopy Studies of Cardiac Muscle Metabolism

NCT00181259

Heart Failure, Congestive

RECRUITING

Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases

NCT04349566

Becker Muscular Dystrophy McArdle Disease Limb-Girdle Muscular Dystrophy Type 2

COMPLETED

Exercise-induced High-sensitivity Troponin Levels as a Predictor for Obstructive Coronary Artery Disease

NCT02626806

Coronary Artery Disease

UNKNOWN

PRE-DETERMINE Cohort Study

NCT01114269

Coronary Artery Disease Left Ventricular Dysfunction Sudden Cardiac Death

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Left Ventricular Function

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be between the ages of 20 - 80 years at study entry
* Provide written informed consent and be able to comply with study procedures, including permission to access medical records
* Have a BMI index equal to or less than 35
* Less than 5% risk of developing coronary artery disease as determined using the Combined Diamond/Forrester and CASS data (ACC Stable CAD Guidelines)

Exclusion Criteria

* Have taken cardioactive drugs within 6 months prior to examination

* These include but are not limited to beta-blockers, calcium channel blockers, and angiotensin converting enzyme inhibitors
* Currently clinically significant chronic or acute illness
* Documented cardiovascular disease
* Possess abnormal cardiac structure and function after examination with routine ECHO

* This may include valvular defects, left ventricular hypertrophy, cardiomyopathies or pericardial disease
* Documented congenital heart conditions or defects
* History of diabetes
* Be unwilling to provide voluntary consent

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes